Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders

Hematology Journal

Volumn 5, Issue 6, 2004, Pages 472-474

  Fabbri, Alberto ^a   Lenoci, Mariapia ^a   Gozzetti, Alessandro ^a   Marotta, Giuseppe ^a   Raspadori, Donatella ^a   Forconi, Francesco ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

CLL; Cyclophosphamide; NHL; Oral fludarabine

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; PREDNISONE; VINCRISTINE SULFATE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ELDERLY CARE; FEMALE; FEVER; HUMAN; INCIDENCE; INFECTION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; VOMITING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIDARABINE;

EID: 11044220192     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200563     Document Type: Article

References (15)

1. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175-188.
2. Plunkett W. Fludarabine: pharmacokinetics, mechanism of action and rationale for combination therapies. Semin Oncol 1993; 20: 2-12.
3. Bellosillo B, Villamour N, Colomer D, Pons G, Montserrat F, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-Cell chronic lymphocytic leumeia. Blood 1999; 94: 2836-2843.
4. Shvidel L, Shtalrid M, Bairey O, Rahimi-Levene N, Lugassy G, Shpilberg O et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphopcytic leukaemia. Leuk Lymphoma 2003; 44: 1947-1950.
5. Hallek M, Schmitt B, Wilhelm M, Busch R, Kroeber A, Fostitsch HP et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL study group. Br J Haematol 2001; 114: 342-348.
6. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koeller GA, Giles Lerner S et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia. J Clin Oncol 2001; 19: 1414-1420.
7. Frewin R, Turner D, Tighe M, Davies S, Johnson S. Combination therapy with fludarabine and cyclophosphamide salvage treatment in lymphoproliferative disorders. Br J Haematol 1999; 104: 612-613.
8. Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F. Low dose fludarabine, and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268-1270.
9. Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-4258.
10. Cheson BD, Bennet JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic lekemia: revisited guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
11. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non Hodgkin lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
13. Bocchia M, Bigazzi C, Marconcini S, Forconi F, Marotta G, Algeri R et al. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment of low grade non Hodgkin lymphomas. Haematologica 1999; 84: 716-720.
14. Hochster HS, Oken MM, Winter JN, Gordon LI, Raphael BG, Bennet JM et al. Phase I of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long term follow up - A report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000; 18: 987-994.
15. Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71-75.